A cost-consequence analysis of the preferential use of secukinumab versus adalimumab for the treatment of psoriatic arthritis Alberto Jiménez-Morales, Rafael Cáliz, Susana Aceituno, Miriam Prades, Carles Blanch

Real-world apremilast use in biologic-naïve psoriatic arthritis patients. Data from Spanish clinical practice Jordi Gratacós-Masmitja, Emma Beltrán Catalán, José Luis Álvarez Vega, Ana Urruticoechea-Arana, Concepción Fito, Francisco Maceiras, Joaquín María Belzunegui Otano, Julia Fernández Melón, Eugenio Chamizo Carmona, Miguel Ángel Abad Hernández, Inmaculada Ros Vilamajó, Sonia Castro Oreiro, Eva Pascual Alfonso, Juan Carlos Torre Alonso

Survival of first line biological and targeted synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis in Chile Marcos Cruces Olivar, Allan D. Burboa, Yolanda M. Gómez